ADMA Biologics, Inc.
ADMA
$16.14
-$0.44-2.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.39% | 12.00% | 13.80% | 40.22% | 59.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.39% | 12.00% | 13.80% | 40.22% | 59.06% |
| Cost of Revenue | -7.14% | -2.63% | 10.09% | 25.58% | 33.15% |
| Gross Profit | 40.24% | 26.76% | 17.01% | 56.23% | 90.84% |
| SG&A Expenses | 0.18% | 17.71% | 33.14% | 52.40% | 58.47% |
| Depreciation & Amortization | 104.00% | 35.71% | -77.46% | -87.05% | -86.63% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.55% | 3.75% | 16.47% | 33.08% | 39.31% |
| Operating Income | 63.74% | 28.69% | 9.18% | 59.85% | 124.99% |
| Income Before Tax | 77.44% | 29.30% | 11.84% | 81.78% | 296.73% |
| Income Tax Expenses | 115.83% | 1,219.88% | 55.13% | 1,000.17% | -- |
| Earnings from Continuing Operations | -55.87% | 1.45% | 6.73% | 51.10% | 734.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.87% | 1.45% | 6.73% | 51.10% | 734.15% |
| EBIT | 63.74% | 28.69% | 9.18% | 59.85% | 124.99% |
| EBITDA | 60.92% | 27.56% | 8.75% | 53.96% | 110.36% |
| EPS Basic | -56.16% | -0.26% | 2.76% | 45.37% | 706.02% |
| Normalized Basic EPS | 70.32% | 32.99% | 10.79% | 75.10% | 203.51% |
| EPS Diluted | -52.82% | 0.00% | 7.69% | 41.39% | 633.63% |
| Normalized Diluted EPS | 72.76% | 35.29% | 12.11% | 75.72% | 192.01% |
| Average Basic Shares Outstanding | 0.65% | 1.72% | 3.90% | 3.89% | 4.63% |
| Average Diluted Shares Outstanding | -0.83% | -0.06% | 2.66% | 3.49% | 8.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |